Trevi Therapeutics
TRVI
77 hedge funds and large institutions have $167M invested in Trevi Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 9 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
4.6% more ownership
Funds ownership: 74.77% → 79.37% (+4.6%)
4% less funds holding
Funds holding: 80 → 77 (-3)
6% less capital invested
Capital invested by funds: $178M → $167M (-$11.3M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$4.1M |
| 2 |
BlackRock
New York
|
+$2.11M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.67M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$1.29M |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
+$1.02M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.49M |
| 2 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$374K |
| 3 |
Renaissance Technologies
New York
|
-$180K |
| 4 |
AI
Atom Investors
Austin,
Texas
|
-$158K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$98.9K |
TRVI Hedge Fund Activity: Q2 2024 in Review
77 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2024, worth a combined $167M — down 6.3% from $178M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of TRVI and 6 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 37 added.
The largest buyer was Ally Bridge Group, opening a new position worth an estimated $4.1M. The largest seller was Rubric Capital Management (New York), cutting an estimated $1.49M.
- 77 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2024, down from 80 in Q1 2024.
- Funds reported $167M of Trevi Therapeutics stock for Q2 2024, down 6.3% quarter-over-quarter.
- 6 funds opened new Trevi Therapeutics positions in Q2 2024 and 9 closed out, a net change of -3 holders.
- The largest Trevi Therapeutics buyer in Q2 2024 was Ally Bridge Group, an estimated $4.1M added.
- The largest Trevi Therapeutics seller in Q2 2024 was Rubric Capital Management (New York), an estimated $1.49M sold.
Based on aggregated 13F filings for Q2 2024.